Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innate Pharma SA ( (FR:IPH) ) just unveiled an announcement.
On September 2, 2025, Innate Pharma S.A. announced its total number of shares and voting rights as of September 1, 2025. The company reported 92,185,473 ordinary shares, 6,419 Preferred Shares 2016, and 7,581 Preferred Shares 2017, with a total of 93,962,943 theoretical voting rights and 93,944,368 exercisable voting rights. This update ensures market transparency and informs stakeholders about the company’s current shareholding structure.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages the innate immune system through its proprietary ANKET® platform, Antibody Drug Conjugates, and monoclonal antibodies. Innate Pharma collaborates with biopharmaceutical companies such as Sanofi and AstraZeneca and is listed on Euronext Paris and Nasdaq.
Average Trading Volume: 163,236
Technical Sentiment Signal: Hold
Current Market Cap: €170M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.